Our therapy transforms the landscape of nervous system regeneration therapies. By integrating advanced epigenetic modulation, we directly promote remyelination, restoring lost neural functions with precision and safety.

While current approaches to neurodegenerative diseases focus largely on managing inflammation, our therapy breaks new ground by reprogramming glial cells at the transcriptional level and activating key repair pathways controlled by epigenetic factors such as histone deacetylase 2 (HDAC2). This technology unlocks new therapeutic possibilities, minimizes side effects, and accelerates the translation of breakthrough science into effective, remyelination-focused treatments.

​

Duman M. et al. (2020). EEF1A1 deacetylation enables transcriptional activation of remyelination. Nature Communications.
Read the paper →